

## CURRICULUM VITAE

### **Caleb Chin Tao Ng, M.D.**

CA Medical license #A144080

#### **Education**

- Undergraduate: University of California, Davis
- Medical School: Loma Linda University School of Medicine

#### **Post-Doctoral Training**

- Internship: Loma Linda University
- Residency: Loma Linda University
- Fellowship: Vitreoretinal Surgery, West Coast Retina, California Pacific Medical Center, San Francisco

#### **Licensure and Board Certification**

- California
- Diplomat, American Board of Ophthalmology

#### **Memberships**

- Member, American Society of Retinal Specialists
- Member, American Academy of Ophthalmology

#### **Awards and Honors**

- Graduated as Valedictorian from Salinas High School
- Regents Full Scholarship to University of California, Davis
- Alpha Omega Honor Society
- John C Affeldt Award, 2nd place Resident Research Presentation
- John C Affeldt Award, 1st place Resident Research Presentation

#### **Bibliography**

1. Huang GO, Engebretsen SR, Smith JC, Wallner CL, Culpepper DJ, Creech JD, **Ng CC**, Mai AT, Chung CS, Olgin G, Arnold DC 2nd, Baldwin DD. Detection of uric acid stones in the ureter using low- and conventional-dose computed tomography. *Urology*. 2014 Sep;84(3):571-4. doi: 10.1016/j.urology.2014.02.021. Epub 2014 Apr 17. PMID: 24746662.
2. Lightfoot M, **Ng C**, Engebretsen S, Wallner C, Huang G, Li R, Alsayouf M, Olgin G, Smith JC, Baldwin DD. Analgesic use and complications following upper pole access for percutaneous nephrolithotomy. *J Endourol*. 2014 Aug;28(8):909-14. doi: 10.1089/end.2014.0035. Epub 2014 Mar 31. PMID: 24548123.
3. **Ng C**, Chalam KV. Endophthalmitis after dropless (Tri-Moxi injection) cataract surgery. *Eur J Ophthalmol*. 2020 Sep;30(5):NP29-NP31. doi: 10.1177/1120672119852505. Epub 2019 Jun 3. PMID: 31155929.
4. Chalam KV, **Ng C**. Assistant Independent Self-retaining Truncated Gonioscopy Contact Lens for Minimally Invasive Glaucoma Surgery. *J Glaucoma*. 2019 Jul;28(7):e128-e130. doi: 10.1097/IJG.0000000000001246. PMID: 30882769.
5. Sierpina DI, **Ng CCT**, Rauser ME, Fan JT. Ciprofloxacin and Conjunctival Flora Resistance after Intravitreal Injection. *Ophthalmol Retina*. 2019 Aug;3(8):710-711. doi: 10.1016/j.oret.2019.04.017. Epub 2019 Apr 22. PMID: 31196818.

6. Griffin SM, McDonald HR, Johnson RN, Jumper JM, Fu AD, Cunningham ET Jr, Kiang L, **Ng CC**, Lujan BJ. FINGERPRINT SIGN OF THE HENLE FIBER LAYER. *Retina*. 2021 Feb 1;41(2):381-386. doi: 10.1097/IAE.0000000000002875. PMID: 32604343; PMCID: PMC7959252.
7. **Ng CC**, Chan CK, Abraham P, Hafner AD. Single nucleotide polymorphism profiles associated with three common phenotypes of advanced age-related macular degeneration. *Acta Ophthalmol*. 2021 Feb;99(1):e133-e134. doi: 10.1111/aos.14498. Epub 2020 Jul 9. PMID: 32643258.
8. **Ng CC**, Carrera WM, McDonald HR, Agarwal A. Heterozygous *CRX* R90W mutation-associated adult-onset macular dystrophy with phenotype analogous to benign concentric annular macular dystrophy. *Ophthalmic Genet*. 2020 Oct;41(5):485-490. doi: 10.1080/13816810.2020.1795890. Epub 2020 Jul 20. PMID: 32689858.
9. **Ng CC**, Jumper JM, Cunningham ET Jr. Multiple evanescent white dot syndrome following influenza immunization - A multimodal imaging study. *Am J Ophthalmol Case Rep*. 2020 Aug 3;19:100845. doi: 10.1016/j.ajoc.2020.100845. PMID: 32885094; PMCID: PMC7453109.
10. **Ng CC**, Chen JJ, Agarwal A, Cunningham ET Jr. Clinical course of von Szily reaction: Case report and comprehensive review of the literature. *Am J Ophthalmol Case Rep*. 2020 Sep 19;20:100927. doi: 10.1016/j.ajoc.2020.100927. PMID: 33015408; PMCID: PMC7522748.
11. Carrera WM, **Ng CC**, Peng MY, Rosco MG, Johnson RN. Cardiopulmonary Resuscitation Retinopathy in an Adult. *Ophthalmol Retina*. 2021 Apr;5(4):388-390. doi: 10.1016/j.oret.2020.09.011. Epub 2020 Sep 18. PMID: 32956859.
12. **Ng CC**, Carrera WM, Peng MY, Agarwal A, Chen JJ, Johnson RN, Jumper JM, McDonald RM. Ocular Injuries Associated with Elastic Exercise Bands. *Retinal Cases & Brief Reports*. 2020 Nov 4. DOI: 10.1097/icb.0000000000001078 PMID: 33165305
13. Carrera WM, **Ng CC**, Desler C, Jumper JM, Agarwal A. Novel FZD4 and LRP5 mutations in a small cohort of patients with familial exudative vitreoretinopathy (FEVR). *Ophthalmic Genetics*. 2020 Dec 10. <https://doi.org/10.1080/13816810.2020.1855664>
14. Carrera W, Rosco MG, Safo M, Peng MY, **Ng C**, Agarwal A. Reactive AA Amyloidosis in the setting of infective endocarditis manifesting as bilateral orbitopathy and choroidopathy. *Retinal Cases & Brief Reports*. 2020 Dec 18. DOI: 10.1097/icb.0000000000001112 PMID: 33394958
15. **Ng CC**, Alsberge JB, Qian Y, Freund KB, Cunningham Jr ET. Vogt-Koyanagi-Harada-like Uveitis Followed by Melanoma-Associated Retinopathy with Focal Chorioretinal Atrophy and Choroidal Neovascularization in a Patient with Metastatic Cutaneous Melanoma. *Retinal Cases & Brief Reports*. 2020 Dec 21. DOI: 10.1097/icb.0000000000001113 PMID: 33394953
16. **Ng CC**, Peng MY, McDonald HR. Massive Delayed Hemorrhagic Choroidal Detachment and Giant Retinal Tear Detachment Following Scleral-Fixated Akreos IOL. *Ophthalmic Surg Lasers Imaging Retina*. 2021 May;52(5):288-292. doi: 10.3928/23258160-20210429-07. Epub 2021 May 1. PMID: 34044718.
17. **Ng CC**, Brill D, Cunningham ET Jr, Burckhard BA, Jumper JM, Heier J, Rifkin LM, Elliott D, McDonald HR, Sobrin L. Catastrophic, Bilateral Retinal Vascular Occlusion after Intravitreal Bevacizumab Injection. *Retin Cases Brief Rep*. 2021 May 10. doi: 10.1097/ICB.0000000000001158. Epub ahead of print. PMID: 33988542.
18. **Ng CC**, Ng JC, Johnson RN, McDonald HR, Agarwal A. Nivolumab-Induced Harada-like Uveitis with Bacillary Detachment Mimicking Choroidal Metastasis. *Retin Cases Brief Rep*. 2021 May 14. doi: 10.1097/ICB.0000000000001165. Epub ahead of print. PMID: 34027908.
19. Jain N, Liao A, Garg SJ, Patel SN, Wykoff CC, Yu HJ, London NJ, Khurana RN, Zacks DN; Macula Society Pentosan Polysulfate Maculopathy Study Group. Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: a Macula Society Collaborative Study. *Ophthalmol Retina*. 2021 Jul 20:S2468-6530(21)00227-X. doi: 10.1016/j.oret.2021.07.004. Epub ahead of print. PMID: 34298229.
20. **Ng CC**, Sy A, Cunningham ET Jr. Rituximab for non-infectious Uveitis and Scleritis. *J Ophthalmic Inflamm Infect*. 2021 Aug 16;11(1):23. doi: 10.1186/s12348-021-00252-4. PMID: 34396463.

21. **Ng CC**, Sy A, Cunningham ET. Rituximab for Treatment of Non-infectious and Non-malignant Orbital Inflammatory Disease. Accepted to Journal of Ophthalmic Inflammation and Infection 6/2021
22. **Ng CC** and Carrera WM, Koppinger J, Saud A, Chen JC, Agarwal A, Johnson RN, Jumper JM, Lujan BJ, McDonald RM. Multimodal Imaging of Soccer Ball-Related Posterior Segment Injuries. In revision with European Journal of Ophthalmology 1/2021
23. Carrera WM, **Ng CC**, Safi M, Burckhard BA, Ng JC, Agarwal A. Non-syndromic retinitis pigmentosa with anomalous macular vessel due to HGSNAT mutation. Submitted to Retinal cases and brief reports 2/21/21
24. **Ng CC**, Suresh S, Rosenbaum J, McDonald HR, Cunningham ET. Occlusive Retinal Vasculitis Associated with Systemic Sclerosis and Antiphospholipid Antibodies. In revision with American Journal of Ophthalmology Case Reports 7/2021
25. **Ng CC**, McDonald HR, Johnson RN, Cunningham ET. Optic Disc Edema with Peripapillary Serous Retinal Detachment as the Presenting Sign of Necrotizing Herpetic Retinitis. In progress
26. **Ng CC**, McDonald HR, Bern BH, Carson MD, Cunningham ET. *Bartonella henselae*-Associated Optic Neuropathy Presenting as a Central Scotoma in the Absence of Overt Papillitis – A Multimodal Imaging Study. In progress
27. **Ng CC**, Kalevar A, Cunningham ET, Dolz-Marco R, Shields C. Pseudohypopyon in Patients With Malignancy – A Comprehensive Review of Published Cases. In progress
28. **Ng CC**, Chen JJ, Kalevar A, Jumper JM, Cunningham ET. Long-Term Management and Treatment Outcomes of Inflammatory Peripapillary Choroidal Neovascularization. In progress

#### Book Chapters

1. Freund KB, Sarraf D, Mieler WF, Yannuzzi LA. The Retinal Atlas, 3rd ed. Elsevier, 2021. Contributing author to chapter 11.

#### Published Abstracts

1. Lightfoot M, **Ng C**, Li R, Alsayouf M, Wallner C, Huang G, Engebretsen S, Olgin G, Baldwin DD. MP27-03 ANALGESIC USE, COMPLICATIONS, AND STONE-FREE RATE FOLLOWING UPPER POLE ACCESS FOR PERCUTANEOUS NEPHROLITHOTOMY. The Journal of Urology. 2014 Apr;191(4S):e275-.
2. **Ng C**, Kim S, Lai MM. Wet Age-Related Macular Degeneration in Asian Americans and non-Asians: An Analysis of Comparative Outcomes. Investigative Ophthalmology & Visual Science. 2018 Jul 13;59(9):5547-.

#### Presentations

1. **Ng CC**, Baldwin DD. (2013) Upper pole access: Does it increase complication rates following percutaneous nephrolithotomy. Poster presented at: Annual Postgraduate Convention, Loma Linda, CA
2. **Ng CC**, Baldwin DD. (2013) Upper pole access: Does it increase complication rates following percutaneous nephrolithotomy. Abstract presented at: 2013 Western Student Medical Research Forum; Carmel, CA
3. **Ng CC**, Kim SC, Lai M. (2018) Wet Age-Related Macular Degeneration in Asian Americans and non-Asians: An Analysis of Comparative Outcomes. Poster presented at ARVO Honolulu, HI
4. **Ng CC**, Kim SC. (2019) Efficacy of Intravitreal Bevacizumab in Treatment of Post-Vitreotomy Vitreous Hemorrhage in Patients with Proliferative Diabetic Retinopathy. Podium presentation at Loma Linda Eye Institute Resident Research Day
5. **Ng CC**, Jumper JM, Cunningham ET. (2020) Multiple Evanescent White Dot Syndrome Following Inactivated Influenza Vaccine. Podium presentation at American Uveitis Society Winter Symposium, Park City, UT.

6. **Ng CC**, McDonald HR, Johnson RN, Agarwal A. (2021) Nivolumab-induced Vogt-Koyanagi-Harada-like Uveitis Masquerading as Choroidal Metastasis. Yannuzzi Grand Rounds, San Francisco

### **Clinical Trials**

1. Title: YOSEMITE: A Phase 3, Multicentered, Randomized, Double-Masked, Parallel-Group, Active-Control Study to Evaluate the Safety and Efficacy of Faricimab in Patients with Diabetic Macular Edema (2018 – Present). Protocol number: GR40349. Sponsor: F. Hoffman-La Roche Ltd. Role: Sub-Investigator
2. Title: PORTAL: A Multicenter, Open-Label Extension Study to Evaluate the long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (2018 – Present). Protocol Number: GR40549. Sponsor: Genentech, Inc. Role: Sub-Investigator
3. Title: ARCHWAY: A Phase 3 Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (2018–Present). Protocol Number: GR40548. Sponsor: Genentech, Inc. Role: Sub-Investigator
4. Title: MERLIN: A Multicenter, Randomized, double-masked Phase 3a Study to assess safety and efficacy of Brolucizumab 6 mg q4 weeks compared to aflibercept 2 mg q4 weeks in Patients with Neovascular Age-Related Macular Degeneration (nAMD) with Persistent Retinal Fluid (2019 – Present). Protocol Number: CRTH258AUS04. Sponsor: Novartis. Role: Sub-Investigator
5. Title: ALTISSIMO: A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration (2019 – Present). Protocol Number: GBV-102-002. Sponsor: Graybug Vision, Inc. Role: Sub-Investigator
6. Title: GALLEGRO: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study To Assess Safety, Tolerability, And Efficacy Of Intravitreal Injections Of FHTR2163 In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration (2019 – Present). Protocol Number: GR40973. Sponsor: Genentech, Inc. Role: Sub-Investigator
7. Title: ISIS: A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (2019 – Present). Protocol Number: 696844-CS5. Sponsor: Ionis Pharmaceuticals, Inc. Role: Sub-Investigator
8. Title: KINGFISHER: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment due to Diabetic Macular Edema (2019–Present). Protocol Number: CRTH258B2305. Sponsor: Novartis Pharmaceuticals Inc. Role: Sub-Investigator
9. Title: PANDA 2: A Phase 3, Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration (2018 – Present). Protocol Number: KHB-1801. Sponsor: Chengdu Kanghong Pharmaceuticals Group Co., Ltd. Role: Sub-Investigator

### **Volunteer and Leadership Activities**

- Lions Eye Foundation, San Francisco
  - Supervised California Pacific Medical Center ophthalmology residents in diagnosis and treatment of retinal pathology for low-income residents of California and Nevada at no cost to patients, and performed vitreoretinal surgery to treat vitreous hemorrhage, epiretinal membrane, rhegmatogenous retinal detachment, traction retinal detachment, and aphakia at no cost to patients.
- Implementation of Globe Rupture Protocol at Two Trauma Hospitals 2017-2019

- Presented evidence for management of globe ruptures with intravenous and intravitreal antibiotics to various hospital committees and department chairs, and then created EMR order sets to facilitate uniform and evidenced based management of globe ruptures at Loma Linda University Medical Center and Riverside University Health System.
- Saddleback, Inc Ophthalmology Mission trip to Pohnpei, Micronesia, 2018
  - Performed cataract surgery, pterygium surgery, and laser treatment for high-risk proliferative diabetic retinopathy
  - Assisted in the first vitreoretinal surgery in the Marshall Islands